CGTX
Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.03
−1.90%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
Market Cap
$97.95M
MomentumView details →
1D Return
−1.90%
YTD Return
−23.70%
RSI (14)
50.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
Market Cap
$97.95M
RSI (14)
50.8
MomentumView details →
1D Return
−1.90%
YTD Return
−23.70%
SummaryUpdated Jun 1, 2026
Cognition Therapeutics, Inc. (NASDAQ:CGTX) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company went public in October 2021 and focuses on developing small molecule therapeutics for age-related degenerative diseases affecting the central nervous system and retina. Cognition Therapeutics is currently advancing multiple clinical trials for its lead drug candidate across several neurodegenerative conditions, with significant backing from National Institutes of Health grants totaling over $170 million in non-dilutive funding.
Similar companies
Latest newsMore news →
Cognition Therapeutics, Inc. reported a second-quarter loss of $0.04 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and the year-ago loss of $0.11 per share.29d agoCognition Therapeutics received written feedback from the FDA agreeing that psychosis associated with dementia with Lewy bodies could be an approvable outcome and aligning on key aspects of a pivotal trial for Zervimesine (CT1812).73d ago